MedPath

Effect of canagliflozin as an alternative drug from DPP-4 inhibitor on heart failure with diabetis melltus : the pilot study "Can canagliflozin HAve Not only hypoGlycemic but cardiac supportive Effect?"

Not Applicable
Conditions
chronic heart failure with type 2 diabetis mellitus
Registration Number
JPRN-UMIN000031563
Lead Sponsor
Osaka Rosai Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. End stage renal failure including eGFR<15ml/min/1.73m2 or dialytic therapy 2. Treated with SGLT2 inhibitor 3. Contraindications of SGLT2 inhibitor 4. Type 1 diabetes mellitus 5. The pregnant, breast feeder 6. BMI<18.5kg/m2

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the change of BNP at 6 months from baseline
Secondary Outcome Measures
NameTimeMethod
1.Vital signs 2.Labolatory data: blood and urinary biomarkers 3.Cardiac function 4.Cardiac vascular event
© Copyright 2025. All Rights Reserved by MedPath